• Je něco špatně v tomto záznamu ?

Impact of Peritoneal Interposition Flap on Patients Undergoing Robot-assisted Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review and Meta-analysis of Randomized Controlled Trials

M. May, C. Gilfrich, J. Bründl, B. Ubrig, JR. Wagner, S. Gloger, V. Student, AS. Merseburger, C. Thomas, SD. Brookman-May, I. Wolff

. 2024 ; 10 (1) : 80-89. [pub] 20230803

Jazyk angličtina Země Nizozemsko

Typ dokumentu metaanalýza, systematický přehled, časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007839

CONTEXT: Symptomatic lymphocele (sLC) occurs at a frequency of 2-10% after robot-assisted radical prostatectomy (RARP) with pelvic lymph node dissection (PLND). Construction of bilateral peritoneal interposition flaps (PIFs) subsequent to completion of RARP + PLND has been introduced to reduce the risk of lymphocele, and was initially evaluated on the basis of retrospective studies. OBJECTIVE: To conduct a systematic review and meta-analysis of only randomized controlled trials (RCTs) evaluating the impact of PIF on the rate of sLC (primary endpoint) and of overall lymphocele (oLC) and Clavien-Dindo grade ≥3 complications (secondary endpoints) to provide the best available evidence. EVIDENCE ACQUISITION: In accordance with the Preferred Reporting Items for Meta-Analyses statement for observational studies in epidemiology, a systematic literature search using the MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE databases up to February 3, 2023 was performed to identify RCTs. The risk of bias (RoB) was assessed using the revised Cochrane RoB tool for randomized trials. Meta-analysis used random-effect models to examine the impact of PIF on the primary and secondary endpoints. EVIDENCE SYNTHESIS: Four RCTs comparing outcomes for patients undergoing RARP + PLND with or without PIF were identified: PIANOFORTE, PerFix, ProLy, and PLUS. PIF was associated with odds ratios of 0.46 (95% confidence interval [CI] 0.23-0.93) for sLC, 0.51 (95% CI 0.38-0.68) for oLC, and 0.41 (95% CI 0.21-0.83) for Clavien-Dindo grade ≥3 complications. Functional impairment resulting from PIF construction was not observed. Heterogeneity was low to moderate, and RoB was low. CONCLUSIONS: PIF should be performed in patients undergoing RARP and simultaneous PLND to prevent or reduce postoperative sLC. PATIENT SUMMARY: A significant proportion of patients undergoing prostate cancer surgery have regional lymph nodes removed. This part of the surgery is associated with a risk of postoperative lymph collections (lymphocele). The risk of lymphocele can be halved via a complication-free surgical modification called a peritoneal interposition flap.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007839
003      
CZ-PrNML
005      
20240423160323.0
007      
ta
008      
240412s2024 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euf.2023.07.007 $2 doi
035    __
$a (PubMed)37541915
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a May, Matthias $u Department of Urology, St. Elisabeth Hospital Straubing, Brothers of Mercy Hospital, Straubing, Germany. Electronic address: matthias.may@klinikum-straubing.de
245    10
$a Impact of Peritoneal Interposition Flap on Patients Undergoing Robot-assisted Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review and Meta-analysis of Randomized Controlled Trials / $c M. May, C. Gilfrich, J. Bründl, B. Ubrig, JR. Wagner, S. Gloger, V. Student, AS. Merseburger, C. Thomas, SD. Brookman-May, I. Wolff
520    9_
$a CONTEXT: Symptomatic lymphocele (sLC) occurs at a frequency of 2-10% after robot-assisted radical prostatectomy (RARP) with pelvic lymph node dissection (PLND). Construction of bilateral peritoneal interposition flaps (PIFs) subsequent to completion of RARP + PLND has been introduced to reduce the risk of lymphocele, and was initially evaluated on the basis of retrospective studies. OBJECTIVE: To conduct a systematic review and meta-analysis of only randomized controlled trials (RCTs) evaluating the impact of PIF on the rate of sLC (primary endpoint) and of overall lymphocele (oLC) and Clavien-Dindo grade ≥3 complications (secondary endpoints) to provide the best available evidence. EVIDENCE ACQUISITION: In accordance with the Preferred Reporting Items for Meta-Analyses statement for observational studies in epidemiology, a systematic literature search using the MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE databases up to February 3, 2023 was performed to identify RCTs. The risk of bias (RoB) was assessed using the revised Cochrane RoB tool for randomized trials. Meta-analysis used random-effect models to examine the impact of PIF on the primary and secondary endpoints. EVIDENCE SYNTHESIS: Four RCTs comparing outcomes for patients undergoing RARP + PLND with or without PIF were identified: PIANOFORTE, PerFix, ProLy, and PLUS. PIF was associated with odds ratios of 0.46 (95% confidence interval [CI] 0.23-0.93) for sLC, 0.51 (95% CI 0.38-0.68) for oLC, and 0.41 (95% CI 0.21-0.83) for Clavien-Dindo grade ≥3 complications. Functional impairment resulting from PIF construction was not observed. Heterogeneity was low to moderate, and RoB was low. CONCLUSIONS: PIF should be performed in patients undergoing RARP and simultaneous PLND to prevent or reduce postoperative sLC. PATIENT SUMMARY: A significant proportion of patients undergoing prostate cancer surgery have regional lymph nodes removed. This part of the surgery is associated with a risk of postoperative lymph collections (lymphocele). The risk of lymphocele can be halved via a complication-free surgical modification called a peritoneal interposition flap.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a robotika $7 D012371
650    12
$a lymfokela $x epidemiologie $x etiologie $x chirurgie $7 D008210
650    12
$a nádory prostaty $x patologie $7 D011471
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a lymfadenektomie $x škodlivé účinky $x metody $7 D008197
650    _2
$a prostatektomie $x škodlivé účinky $x metody $7 D011468
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Gilfrich, Christian $u Department of Urology, St. Elisabeth Hospital Straubing, Brothers of Mercy Hospital, Straubing, Germany
700    1_
$a Bründl, Johannes $u Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
700    1_
$a Ubrig, Burkhard $u Center for Minimally Invasive and Robotic Urology, Augusta Hospital Bochum, Witten/Herdecke University, Bochum, Germany
700    1_
$a Wagner, Joseph R $u Urology Division, Hartford Healthcare Medical Group, Hartford Hospital, Hartford, CT, USA
700    1_
$a Gloger, Simon $u Center for Minimally Invasive and Robotic Urology, Augusta Hospital Bochum, Witten/Herdecke University, Bochum, Germany
700    1_
$a Student, Vladimir $u Department of Urology, University Hospital Olomouc, Olomouc, Czechia
700    1_
$a Merseburger, Axel S $u Department of Urology, University Hospital Schleswig-Holstein, Luebeck, Germany
700    1_
$a Thomas, Christian $u Department of Urology, University Hospital Carl Gustav Carus, University Hospital of the Technical University of Dresden, Dresden, Germany
700    1_
$a Brookman-May, Sabine D $u Department of Urology, Campus Grosshadern, Ludwig-Maximilians University, Munich, Germany; Janssen Pharma Research and Development, Spring House, PA, USA
700    1_
$a Wolff, Ingmar $u Department of Urology, University Medicine Greifswald, Greifswald, Germany
773    0_
$w MED00193513 $t European urology focus $x 2405-4569 $g Roč. 10, č. 1 (2024), s. 80-89
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37541915 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160319 $b ABA008
999    __
$a ok $b bmc $g 2081692 $s 1217606
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 10 $c 1 $d 80-89 $e 20230803 $i 2405-4569 $m European urology focus $n Eur Urol Focus $x MED00193513
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace